These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24296108)

  • 1. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.
    Poveda A; Ray-Coquard I; Romero I; Lopez-Guerrero JA; Colombo N
    Cancer Treat Rev; 2014 Apr; 40(3):366-75. PubMed ID: 24296108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
    López-Guerrero JA; Romero I; Poveda A
    Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
    Colombo N
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S12-6. PubMed ID: 21540666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
    Sehouli J; Alfaro V; González-Martín A
    Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
    Khokhlova SV; Cherkasova MV; Orel NF; Limareva SV; Bazaeva IIa; Gorbunova VA
    Vestn Ross Akad Med Nauk; 2013; (11):115-21. PubMed ID: 24640740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E; Herzog TJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Monk BJ; Dalton H; Benjamin I; Tanović A
    Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
    Boccia SM; Sassu CM; Ergasti R; Vertechy L; Apostol AI; Palluzzi E; Fagotti A; Scambia G; Marchetti C
    Drug Des Devel Ther; 2024; 18():2021-2032. PubMed ID: 38863768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
    Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
    Colombo N; Hardy-Bessard AC; Ferrandina G; Marth C; Romero I
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):11-19. PubMed ID: 27797622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Colombo N
    Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Adam JP; Boumedien F; Letarte N; Provencher D
    Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
    Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
    Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
    Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
    Kaye SB; Colombo N; Monk BJ; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Vergote I; Lebedinsky C; Parekh T; Santabárbara P; Park YC; Nieto A; Poveda A
    Ann Oncol; 2011 Jan; 22(1):49-58. PubMed ID: 20643863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
    Monk BJ; Coleman RL
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin: Supportive care strategies and safety profile.
    Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.